Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05667740




Registration number
NCT05667740
Ethics application status
Date submitted
19/12/2022
Date registered
29/12/2022
Date last updated
23/02/2023

Titles & IDs
Public title
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
Scientific title
A Phase 1, Randomised, Placebo-controlled, Double-blind, Sequential Ascending-dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Healthy Adults
Secondary ID [1] 0 0
GPNV-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pneumococcal Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Gamma-PN3
Other interventions - Prevenar-13
Other interventions - Pneumovax-23
Treatment: Drugs - Placebo

Experimental: Gamma-PN3 - Inactivated whole-cell pneumococcal vaccine at 50, 250 or 1000 mcg of protein content.
One dose on Day 1 and second dose Day 29

Placebo Comparator: Placebo - Saline on Day 1 and second dose Day 29

Active Comparator: Prevenar-13 - Licensed pneumococcal vaccine on Day 1 and saline on Day 29

Active Comparator: Pneumovax-23 - Licensed pneumococcal vaccine on Day 1 and saline on Day 29


Other interventions: Gamma-PN3
Inactivated whole-cell pneumococcal vaccine

Other interventions: Prevenar-13
Licensed polysaccharide conjugate pneumococcal vaccine

Other interventions: Pneumovax-23
Licensed polysaccharide pneumococcal vaccine

Treatment: Drugs: Placebo
Saline
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse events and clinical laboratory measures
Timepoint [1] 0 0
57 days
Primary outcome [2] 0 0
Immunogenicity
Timepoint [2] 0 0
57 days
Secondary outcome [1] 0 0
OPKA response
Timepoint [1] 0 0
57 days

Eligibility
Key inclusion criteria
1. Male or female volunteers aged 50 to 69 years inclusive at Screening.

2. In good health as determined by the outcome of medical history, physical examination,
and clinical judgement by the Investigator. Chronic stable non-inflammatory conditions
such as hypertension, hyperlipidemia, well-controlled type 2 diabetes, stable asthma,
controlled psychiatric conditions such as anxiety or depression, stable ischemic heart
disease without heart failure are permitted, as determined by the Investigator.

3. Willing and able to give voluntary written informed consent before screening
assessments commence.

4. Vital signs within the following ranges (inclusive):

- Body temperature 35.5 to 37.7°C

- Heart rate 50 to 100 beats per minute

- Respiratory rate 12 to 22 breaths per minute

- Systolic blood pressure 90 to 160 mmHg

- Diastolic blood pressure 50 to 95 mmHg

5. 12-lead electrocardiogram (ECG) parameters within the following ranges:

- QTcB & QTcF - males =450 msec. females =470 msec

- PR 100 to 240 msec inclusive

- HR 50 to 100 bpm inclusive

6. Willing and able to communicate with the Investigator and study team and understands
the requirements of the study.

7. Willing and able to undertake the study visits and all assessments, including
possessing a suitable device and access to the internet for using the web-based
electronic diary (e.g., smartphone, tablet, or computer) and able to use the device
for this purpose.

8. Vaccinated against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2;
COVID-19) as per State Health advice at the time of recruitment.
Minimum age
50 Years
Maximum age
69 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. History of a previous Pneumovax 23® vaccination.

2. History of a previous Prevenar 13® vaccination.

3. Splenectomy or cochlear implant, due to likelihood of having received pneumococcal
vaccination at age less than 70 years.

4. Positive serology blood test for human immunodeficiency virus (HIV) antibodies,
hepatitis B virus (HBV) surface antigen or Hepatitis C virus (HCV) antibodies.

5. Infectious disease including but not limited to COVID-19 and influenza within 30 days
before Screening and any time between Screening and Day 1 first dose, as this may
confound immune response to study vaccine.

6. Liver function tests (including aspartate aminotransferase [AST], alanine
aminotransferase [ALT], bilirubin) >1.5 upper limit of normal (ULN).

7. Clinically significant abnormalities in laboratory tests (biochemistry, haematology,
coagulation, urinalysis), physical examination, 12-lead ECG or vital signs during the
Screening period that, in the opinion of the Investigator, would affect immune
response to vaccination and/or ability to fully participate in the study and/or not be
in the individual's best interest to participate in the study. One retest per
abnormality is permitted.

8. Participation in another clinical study of any investigational or licensed product
(including investigational COVID-19 vaccines, drugs, medical devices) or medical
procedure within 4 weeks from last study visit before screening.

9. Plan to have a vaccine during the study period including COVID-19 booster.

10. Have had a live vaccine within three months of the first dose of study product or any
other vaccine (including any COVID-19 vaccine) within 28 days of the first dose of
study product. Examples of live vaccines include, but are not limited to the
following: measles, mumps, rubella, chicken pox/zoster, monkeypox, yellow fever,
rabies, Bacillus Calmette-Guérin, and typhoid (oral) vaccines. Seasonal influenza
vaccines for injection are generally killed virus vaccines and are permitted if
administered at least 28 days before the first dose of study treatment and not during
the enrollment or the study period. However, intranasal influenza vaccines are live
attenuated vaccines and are not permitted within three months of first dose.

11. Have received blood or blood-derived products in the last three months before
screening, which might interfere with assessment of the immune response.

12. Known or suspected congenital or acquired immunodeficiency; or receipt of
immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
the last six months before screening; or long-term systemic corticosteroid therapy
(prednisone or equivalent for more than two consecutive weeks within the last month
before screening, depot or intraarticular steroids within 3 months before screening).

13. A systemic inflammatory condition such as rheumatoid arthritis or inflammatory bowel
disease.

14. History of severe allergic reaction e.g., severe cutaneous adverse reaction or
anaphylaxis to any medicinal product or to any of the study products, including
excipients.

15. Current alcohol abuse (> 21 U/week for men and 14 U/week for women), substance
dependence including nicotine/tobacco smoking (defined as more than 5 cigarettes or
tobacco/nicotine equivalent per day; smoking or vaping will not be permitted while at
the study unit), any use of illicit drugs or other addiction which might interfere
with the ability to comply with study procedures in the opinion of the Investigator,
positive drugs of abuse screen (tricyclic antidepressants are not exclusionary if
consistent with medical history) or positive alcohol breath test at Screening or
pre-dose. One re-test permitted for drugs of abuse screen where justified (e.g., false
positive suspected).

16. Clinically significant chronic illness that, in the opinion of the Investigator, is at
a stage where it might interfere with study conduct or completion. Examples include
congestive heart failure, COAD with breathlessness interfering with daily activities;
psychiatric conditions, poorly controlled asthma, or diabetes

17. Any chronic medical condition e.g., asthma, gout, which is likely to need systemic
corticosteroid therapy during the study. -

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2023
Actual
Sample size
Target
117
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GPN Vaccines
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety
and markers of efficacy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05667740
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sepehr Shakib, MD
Address 0 0
CMAX
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Tim Hirst, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 420 942 824
Fax 0 0
Email 0 0
tim@gpnvaccines.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05667740